+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Post-ADA Report

  • ID: 4846144
  • Report
  • July 2019
  • Region: Global
  • 97 pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now
Overview
The American Diabetes Association (ADA) 79th Scientific Sessions was held in San Francisco, CA from 7–11 June 2019.

This year's conference was filled with major sessions dedicated to outcomes trials and Phase III programs, notably: first details from Trulicity's REWIND (LLY, Sumitomo Dainippon) cardiovascular outcomes trial (CVOT), first conference presentation of oral semaglutide's (NVO, EMIS) PIONEER 6 CV safety study and other trials from its Phase III program, first ADA presentation of Invokana's (JNJ, Mitsubishi Tanabe, Daiichi Sankyo) CREDENCE cardiorenal outcomes trial, an update with new CV and renal details from Farxiga's (AZN, Ono) DECLARE-TIMI 58 CVOT, first details from Tradjenta's (Boehringer, LLY) CAROLINA CVOT trial against glimepiride, and first ADA presentation of Tradjenta's CARMELINA CVOT against placebo.
Note: Product cover images may vary from those shown
Selected Abstracts Featured at the American Diabetes Association 79th Scientific Sessions..13
  • GLP-1 Agonists.13
  • Trulicity (LLY, Sumitomo Dainippon; NDA Cardiovascular Disease).13
  • Trulicity (LLY, Sumitomo Dainippon; Approved Type 2)24
  • Oral Semaglutide (NVO, EMIS; NDA Type 2)..25
GLP-1 Co-Agonists
  • LY3298176 (LLY; Phase III Type 2)
  • Other GLP-1 Co-Agonists News
SGLT Inhibitors
  • Invokana (JNJ, Mitsubishi Tanabe, Daiichi Sankyo; NDA Diabetic Nephropathy)
  • Other SGLT Inhibitor News
DPP-IV Inhibitors48
  • Tradjenta (Boehringer, LLY; Approved Type 2)
Insulins
  • LY900014 (LLY; Phase III Type 1 and Type 2)
  • Dance 501 (Dance; Phase II Type 2)
  • Afrezza (MNKD; Approved Type 1)
  • Afrezza (MNKD; Approved Type 2)
  • SAR341402 (SNY; Phase III Type 1)
  • SAR341402 (SNY; Phase III Type 1)
  • SAR341402 (SNY; Phase III Type 1)
  • Other Insulin News63
Prevention of Type 1 Diabetes
  • PRV-031 (teplizumab; PRVB, MGNX; Phase III Type 1)
Non-Alcoholic Steatohepatitis (NASH)
  • MSDC-0602K (Cirius Therapeutics; Phase II NASH)
  • LY3298176 (LLY; Phase I NASH)
  • MK-3655 (formerly NGM313; MRK, NGM; Phase I NASH)
  • Other NASH News
Notes on Dyslipidemia
  • Vascepa (AMRN; Approved Hypertriglyceridemia, NDA Cardiovascular Disease)
  • Apheresis and PCSK9 inhibitors
Other Mechanisms
  • Other Mechanisms News
Devices
  • Artificial Pancreas System – Tandem (TNDM, DXCM; Approved Type I)
  • Artificial Pancreas System – Tandem (TNDM, DXCM; Approved Type I)
  • MiniMed 780G (MDT; Development Type 1)
  • MiniMed 670G (MDT; Approved Type 1)
  • FreeStyle Libre Flash Glucose Monitoring System (ABT; Approved Type 2)
  • Other Device News
List of Biomedtracker and Meddevicetracker ADA 2019 Events
Note: Product cover images may vary from those shown
Adroll
adroll